These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 9159748)

  • 21. Is levodopa toxic to human substantia nigra?
    Rajput AH; Fenton Me; Birdi S; Macaulay R
    Mov Disord; 1997 Sep; 12(5):634-8. PubMed ID: 9380042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [L-dopa/benserazide during pregnancy in a patient with juvenile parkinsonism].
    Arai H; Shinotoh H; Hattori T
    Rinsho Shinkeigaku; 1997 Mar; 37(3):264-5. PubMed ID: 9217430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa: back to the future.
    Zappia M; Colosimo C; Poewe W
    J Neurol; 2010 Nov; 257(Suppl 2):S247-8. PubMed ID: 21080184
    [No Abstract]   [Full Text] [Related]  

  • 24. Square-wave action dystonia in Parkinson's disease.
    van den Munckhof P; Lenz FA; Chase TN
    Mov Disord; 1998 Mar; 13(2):354-6. PubMed ID: 9539355
    [No Abstract]   [Full Text] [Related]  

  • 25. Levodopa response in Parkinsonism with multiple mitochondrial DNA deletions.
    Wilcox RA; Churchyard A; Dahl HH; Hutchison WM; Kirby DM; Thyagarajan D
    Mov Disord; 2007 May; 22(7):1020-3. PubMed ID: 17357142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa-responsive parkinsonism in hereditary spastic paraplegia with thin corpus callosum.
    Kang SY; Lee MH; Lee SK; Sohn YH
    Parkinsonism Relat Disord; 2004 Oct; 10(7):425-7. PubMed ID: 15465400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Motor symptoms in Parkinson disease].
    Larsen JP; Beiske AG; Bekkelund SI; Dietrichs E; Tysnes OB; Vilming ST; Aasly JO
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2068-71. PubMed ID: 18846123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism.
    Snow BJ; Nygaard TG; Takahashi H; Calne DB
    Ann Neurol; 1993 Nov; 34(5):733-8. PubMed ID: 8239569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopa-responsive dystonia (Segawa disease) -like disease accompanied by mental retardation: a case report.
    Nagata E; Kosakai A; Tanaka K; Segawa M; Fujioka H; Shintaku H; Suzuki N
    Mov Disord; 2007 Jun; 22(8):1202-3. PubMed ID: 17469209
    [No Abstract]   [Full Text] [Related]  

  • 32. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinguishing early-onset PD from dopa-responsive dystonia with transcranial sonography.
    Hagenah JM; Hedrich K; Becker B; Pramstaller PP; Seidel G; Klein C
    Neurology; 2006 Jun; 66(12):1951-2. PubMed ID: 16801671
    [No Abstract]   [Full Text] [Related]  

  • 35. Asparagus and jejunal-through-PEG: an unhappy encounter in intrajejunal levodopa infusion therapy.
    Schrader C; Böselt S; Wedemeyer J; Dressler D; Weismüller TJ
    Parkinsonism Relat Disord; 2011 Jan; 17(1):67-9. PubMed ID: 20933456
    [No Abstract]   [Full Text] [Related]  

  • 36. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-Parkinsonism syndrome).
    Lew MF; Shindo M; Moskowitz CB; Wilhelmsen KC; Fahn S; Waters CH
    Mov Disord; 1994 May; 9(3):318-20. PubMed ID: 8041372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 39. Who dropped the ball on L-DOPA? A patient's lament.
    Palfreman J
    J Parkinsons Dis; 2014; 4(3):313-6. PubMed ID: 24946968
    [No Abstract]   [Full Text] [Related]  

  • 40. [L-dopa effective parkinsonism appeared after shunt revision of the aqueductal stenosis: report of two cases].
    Ochiai H; Yamakawa Y; Miyata S; Kawasoe T
    No To Shinkei; 2000 May; 52(5):425-9. PubMed ID: 10845212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.